二甲双胍对PCOS孕妇雄激素的影响:非肥胖及男性胎儿亚组分析
该研究基于随机安慰剂对照多中心试验的事后分析及健康孕妇纵向研究,纳入262例PCOS孕妇和119例对照。PCOS孕妇孕期各时间点雄激素水平均高于对照;总体二甲双胍对雄激素无影响,但亚组分析显示非肥胖PCOS孕妇中二甲双胍降低雄烯二酮(P=0.019),男性胎儿孕妇中降低雄烯二酮(P=0.036)、睾酮(P=0.023)和SHBG(P=0.010)。
要点
- PCOS孕妇孕期雄激素水平持续高于健康对照。
- 总体PCOS孕妇中二甲双胍对雄激素无显著影响。
- 非肥胖或怀男性胎儿的PCOS孕妇中二甲双胍可能降低雄激素。
核心结论
- 二甲双胍对PCOS孕妇总体雄激素水平无影响。
- 亚组分析中非肥胖PCOS孕妇及怀男性胎儿的PCOS孕妇观察到二甲双胍的降雄激素作用。
研究设计与样本
- 随机安慰剂对照多中心研究的事后分析,联合健康孕妇纵向单中心研究。
- 共纳入262例PCOS孕妇和119例健康对照,PCOS孕妇随机接受二甲双胍2g/日或安慰剂,从孕早期至分娩。
主要发现
- PCOS孕妇孕期各时间点雄烯二酮、睾酮和游离睾酮指数均高于健康对照,SHBG低于对照。
- 总体PCOS孕妇中二甲双胍对雄烯二酮、睾酮、SHBG和游离睾酮指数无影响。
- 非肥胖PCOS孕妇中二甲双胍降低雄烯二酮(P=0.019)。
- 怀男性胎儿的PCOS孕妇中二甲双胍降低雄烯二酮(P=0.036)、睾酮(P=0.023)和SHBG(P=0.010)。
临床怎么用
- PCOS孕妇总体人群不推荐使用二甲双胍以降低母体雄激素水平。
- 对非肥胖或怀男性胎儿的PCOS孕妇,二甲双胍可能作为个体化降雄激素的选择,需进一步验证。
局限性
- 亚组分析为事后分析,结果需谨慎解读。
- 研究未报告亚组样本量及置信区间,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Large, longitudinal studies on androgen levels in pregnant women with polycystic ovary syndrome (PCOS) are lacking. While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood. OBJECTIVE: To describe androgen patterns in pregnant women with PCOS and in healthy control women, and to explore the potential effects of metformin on maternal androgen levels in PCOS. DESIGN AND SETTING: A post hoc analysis from a randomized, placebo-controlled, multicenter study carried out at 11 secondary care centers and a longitudinal single-center study on healthy pregnant women in Norway. PARTICIPANTS: A total of 262 women with PCOS and 119 controls. INTERVENTION: The participants with PCOS were randomly assigned to metformin (2 g daily) or placebo, from first trimester to delivery. MAIN OUTCOME MEASURES: Androstenedione (A4), testosterone (T), sex-hormone binding globulin (SHBG), and free testosterone index (FTI) at 4 time points in pregnancy. RESULTS: Women with PCOS versus healthy controls had higher A4, T, and FTI, and lower SHBG at all measured time points in pregnancy. In the overall cohort of women with PCOS, metformin had no effect on A4, T, SHBG, and FTI. In subgroup analyses, metformin reduced A4 (P = 0.019) in nonobese women. Metformin also reduced A4 (P = 0.036), T (P = 0.023), and SHBG (P = 0.010) levels through pregnancy in mothers with a male fetus. CONCLUSION: Metformin had no effect on maternal androgens in PCOS pregnancies. In subgroup analyses, a modest androgen-lowering effect was observed in nonobese women with PCOS. In PCOS women carrying a male fetus, metformin exhibited an androgen-lowering effect.
引用
- Andræ F, Abbott D, Stridsklev S, et al. Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. J Clin Endocrinol Metab. 2020. PMID: 32866967. doi:10.1210/clinem/dgaa605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。